Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antibiotic
cephalosporin |
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J01DI54
|
| gptkbp:CASNumber |
668270-12-0
|
| gptkbp:combines |
tazobactam
|
| gptkbp:developedBy |
gptkb:Cubist_Pharmaceuticals
|
| gptkbp:hasMolecularFormula |
C23H30N6O10S2
|
| https://www.w3.org/2000/01/rdf-schema#label |
ceftolozane
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Zerbaxa
|
| gptkbp:mechanismOfAction |
inhibits bacterial cell wall synthesis
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
diarrhea headache |
| gptkbp:spectrumOfActivity |
gptkb:Pseudomonas_aeruginosa
Gram-negative bacteria |
| gptkbp:usedFor |
bacterial infections
complicated urinary tract infections complicated intra-abdominal infections |
| gptkbp:bfsParent |
gptkb:Zerbaxa
|
| gptkbp:bfsLayer |
6
|